| Parameter |
Control group (Group I)
(n=20) |
Group II (50 benign breast tumor patients) |
Group III (77 malignant breast tumor patients) |
| Non-metastatic (Group III a) |
Metastatic (Group III b) |
| Erythrocyte MDA (μmol/ml packed RBCs) |
7.11 ± 1.07 |
10.8 ± 2.49 (a) |
14.70 ±0.885 (a) |
21 ± 2.72 (a, c) |
| 18.00 ± 3.81 (a, b) |
| Plasma MDA (nmol/ml) |
0.59 ± 0.11 |
0.88 ± 0.22 (a) |
1.26 ± 0.08 (a) |
1.59 ± 0.19 (a, c) |
| 1.44 ± 0.22 (a, b) |
| SOD (%) |
58.86 ± 3.44 |
49.79 ± 4.71 (a) |
24.36 ± 1.8 (a) |
19.61 ± 4.68 (a, c) |
| 21.41 ± 4.52 (a, b) |
| CAT ( μmol/SEC/ml) |
0.73 ± 0.09 |
0.58 ± 0.09 (a) |
0.41 ± 0.05 (a) |
0.31 ± 0.06 (a, c) |
| 0.36 ± 0.07 (a, b) |
| GSH (mmol/L) |
1667.8 ± 176.3 |
1526.8 ± 141.1 (a) |
1150.6 ± 242.4 (a) |
956.4 ± 206.3 (a, c) |
| 1053.62 ± 240.61 (a,b) |
| GST ( μmol/min/ml) |
3.59 ± 0.22 |
2.94 ± 0.81 (a) |
2.71 ± 0.42 (a) |
2.39 ± 0.27 (a, c) |
| 2.53 ± 0.38 (a,b) |
| Nitric oxide ( μmol/L) |
11.85 ± 2.2 |
15.51 ± 1.85 (a) |
18.78 ± 1.31 (a) |
20.59 ± 2.38 (a, c) |
| 19.94 ± 2.42 (a, b) |
|
